Arbekacin is a broad-spectrum aminoglycoside licensed for systemic use in Japan and under clinical development as an inhalation solution in the United States. We evaluated the occurrence of organisms isolated from pneumonias in U.S. hospitalized patients (PHP), including ventilator-associated pneumonia (VAP), and the in vitro activity of arbekacin. Organism frequency was evaluated from a collection of 2,203 bacterial isolates (339 from VAP) consecutively collected from 25 medical centers in 2012 through the SENTRY Antimicrobial Surveillance Program. Arbekacin activity was tested against 904 isolates from PHP collected in 2012 from 62 U.S. medical centers and 303 multidrug-resistant (MDR) organisms collected worldwide in 2009 and 2010 from various infection types. Susceptibility to arbekacin and comparator agents was evaluated by the reference broth microdilution method. The four most common organisms from PHP were Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella spp., and Enterobacter spp. The highest arbekacin MIC among S. aureus isolates from PHP (43% methicillin-resistant S. aureus [MRSA]) was 4 g/ml. Among P. aeruginosa isolates from PHP, only one had an arbekacin MIC of >16 g/ml (MIC 50 and MIC 90 , 1 and 4 g/ml), and susceptibility rates for gentamicin, tobramycin, and amikacin were 88.0, 90.0, and 98.0%, respectively. Arbekacin (MIC 50 , 2 g/ml) and tobramycin (MIC 50 , 4 g/ml) were the most potent aminoglycosides tested against Acinetobacter baumannii. Against Enterobacteriaceae from PHP, arbekacin and gentamicin (MIC 50 and MIC 90 , 0.25 to 1 and 1 to 8 g/ml for both compounds) were generally more potent than tobramycin (MIC 50 and MIC 90 , 0.25 to 2 and 1 to 32 g/ml) and amikacin (MIC 50 and MIC 90 , 1 to 2 and 2 to 32 g/ml). Arbekacin also demonstrated potent in vitro activity against a worldwide collection of well-characterized MDR Gram-negative and MRSA strains.
A
rbekacin is a broad-spectrum aminoglycoside licensed for systemic use in Japan, where it is largely used to treat methicillin-resistant Staphylococcus aureus (MRSA) infections (1) (2) (3) . Arbekacin inhibits protein synthesis by binding both 50S and 30S ribosomal subunits, and it is highly stable to most aminoglycoside-modifying enzymes produced by S. aureus (4) . The arbekacin spectrum of activity also includes Enterobacteriaceae species and nonfermentative Gram-negative bacilli, such as Pseudomonas aeruginosa and Acinetobacter spp. (5) (6) (7) .
Although arbekacin has demonstrated a broad spectrum of in vitro activity, it is licensed in Japan only for treatment of septicemia and pneumonia caused by MRSA. In the United States, arbekacin is under clinical development for the treatment of hospital-associated and ventilator-associated bacterial pneumonia (HABP/VABP) as an inhalation solution (development code ME1100) (8) (9) (10) . We evaluated the frequency of occurrence of organisms causing pneumonia in hospitalized patients (PHP), including ventilator-associated pneumonias (VAP), in the SENTRY Antimicrobial Surveillance Program (United States, 2012), and the activity of arbekacin was assessed against selected isolates from PHP. In addition, we evaluated the activity of arbekacin against a global collection of well-characterized multidrug-resistant (MDR) strains from various infections sites.
MATERIALS AND METHODS
Frequency of occurrence of bacterial organisms from PHP. Consecutive unique bacterial isolates were cultured from patients with pneumonia in a prevalence sampling design. Isolates were collected from 25 medical centers distributed across all nine U.S. Census Regions in 2012 as part of the SENTRY Program (11) . Each participant center was requested to collect 100 consecutive bacterial isolates from lower respiratory tract sites determined to be significant by local criteria as the reported probable cause of pneumonia. Only isolates from invasive sampling (transtracheal aspiration, bronchoalveolar lavage, protected brush samples, qualified sputum samples, etc.) were accepted. The frequency of occurrence of organisms from patients with VAP and the frequency of those with pneumonia that was not ventilator associated (all cases excluding VAP) were separately analyzed.
Organisms from PHP tested against arbekacin. This collection includes isolates from the 25 U.S. medical centers that participated in the 2012 SENTRY Program (described above) as well as isolates from 37 additional U.S. medical centers. Thus, the isolates (n ϭ 904) were collected from 62 U.S. medical centers in 2012, from patients hospitalized with bacterial pneumonia, including VAP. The most common specimen types were sputum (41.3%), tracheal aspirate (27.0%), bronchoalveolar lavage/ wash (17.9%), and endotracheal tube (7.4%). Isolates were randomly selected and had patterns of susceptibility to key antimicrobial agents consistent with those observed in the SENTRY Program in the United States for 2012.
Resistant subsets tested against arbekacin. The organism collection (n ϭ 303) comprised extended-spectrum-␤-lactamase (ESBL)- Isolates were tested for ␤-lactamase-encoding genes using the microarray-based assay Check-MDR CT101 kit (Check-points, Wageningen, Netherlands). The assay was performed according to the manufacturer's instructions. This kit has the capability to detect CTX-M groups 1, 2, 8 ϩ 25, and 9, wild-type (WT) and ESBL TEM, WT and ESBL SHV, ACC, ACT/MIR, CMYII, DHA, FOX, KPC, and NDM-1 (12) .
Susceptibility testing. Reference broth microdilution tests were conducted according to the Clinical and Laboratory Standards Institute (CLSI M07-A9) (13) methods. S. aureus and Gram-negative bacilli were tested in cation-adjusted Mueller-Hinton broth (CA-MHB), Streptococcus pneumoniae isolates were tested in CA-MHB supplemented with 2.5 to 5% lysed horse blood, and Haemophilus influenzae strains were tested in Haemophilus test medium (HTM). CLSI interpretative criteria (M100-S24) (14, 15) were applied for the comparator agents. Concurrent testing of quality control (QC) strains per M07-A9 (13) and M100-S24 (14) 
RESULTS
Frequency of occurrence of bacterial organisms from PHP. The most frequently isolated organisms from patients with non-VAP and VAP are shown in Fig. 1 and 2 , respectively. The main differences in the frequency and rank order of organisms between non-VAP and VAP patients were as follows: (i) S. aureus ranked first in non-VAP patients (34.1% of total) and second in VAP patients (28.3%), whereas P. aeruginosa ranked second in non-VAP patients (20.0%) and first in VAP patients (29.2%), and (ii) Serratia marcescens was more frequently isolated from VAP patients (5.9%; fifth most common) than non-VAP patients (3.1%; ninth most common). Of note, Stenotrophomonas maltophilia and Acinetobacter spp. exhibited similar frequencies among non-VAP patients (4.8 and 3.5%, respectively) compared to VAP patients (4.7 and 2.7%, respectively).
Antimicrobial activity of arbekacin and comparators tested against organisms from PHP. When arbekacin was tested against S. aureus (43.0% MRSA), its potency (MIC 50 , 0.25 g/ml, and MIC 90 , 0.5 g/ml; highest MIC, 4 g/ml) was very similar to that of gentamicin (MIC 50 , 0.25 g/ml, and MIC 90 , 0.5 g/ml) and greater than those of tobramycin (MIC 50 , 0.5 g/ml, and MIC 90 , Ͼ128 g/ml) and amikacin (MIC 50 , 4 g/ml, and MIC 90 , 16 g/ ml). Susceptibility rates (CLSI) for gentamicin, tobramycin, and amikacin were 95.0, 76.0, and 96.0%, respectively. Moreover, MICs of Ն32 g/ml were observed for all three comparative aminoglycosides (Tables 1 and 2 ). All S. aureus isolates were susceptible to vancomycin (MIC 50 and MIC 90 , 1 g/ml), linezolid (MIC 50 , 1 g/ml and MIC 90 , 2 g/ml), and daptomycin (MIC 50 , 0.25 g/ml and MIC 90 , 0.5 g/ml) ( Table 2) .
Tobramycin (MIC 50 , 0.5 g/ml, and MIC 90 , 4 g/ml; 90.0% susceptible) and arbekacin (MIC 50 , 1 g/ml, and MIC 90 , 4 g/ml; 96.0% inhibited at Յ4 g/ml) were the most potent (i.e., they had the lowest MIC 50 and MIC 90 values) aminoglycosides tested against P. aeruginosa, followed by gentamicin (MIC 50 , 2 g/ml, and MIC 90 , 16 g/ml; 88.0% susceptible) and amikacin (MIC 50 , 4 g/ml, and MIC 90 , 8 g/ml; 98.0% susceptible) ( Table 1) . P. aeruginosa susceptibility (CLSI and EUCAST criteria) to ␤-lactams was highest for ceftazidime (86.0%), followed by piperacillin-tazobactam (78.0%), cefepime (77.0%), and meropenem (75.0%) ( Table 2 ). All isolates were susceptible to colistin (MIC 50 , 0.5 g/ml, and MIC 90 , 1 g/ml) ( Table 2) .
Arbekacin (MIC 50 , 2 g/ml, and MIC 90 , Ͼ128 g/ml; 65.0% inhibited at Յ4 g/ml) and tobramycin (MIC 50 , 4 g/ml, and MIC 90 , Ͼ128 g/ml; 51.0% susceptible at Յ4 g/ml [CLSI]) were also the most potent aminoglycosides tested against A. baumannii (Table 1) , whereas against Enterobacteriaceae species, arbekacin and gentamicin (MIC 50 , 0.25 to 1 g/ml, and MIC 90 , 1 to 8 g/ml for both compounds) were generally more potent than tobramycin (MIC 50 , 0.25 to 2 g/ml, and MIC 90 , 1 to 32 g/ml) and amikacin (MIC 50 , 1 to 2 g/ml, and MIC 90 , 2 to 32 g/ml) ( Table 1) . Among the ␤-lactam compounds, ceftazidime was active against 77.5% of K. pneumoniae (MIC 50 , 0.25 g/ml, and MIC 90 , Ͼ128 g/ml) and 72.0% of Enterobacter (MIC 50 , 0.25 g/ml, and MIC 90 , 64 g/ml) strains, whereas meropenem inhibited 91.2% of K. pneumoniae (MIC 50 , Յ0.06 g/ml, and MIC 90 , 0.12 g/ml) and 100.0% of Enterobacter (MIC 50 and MIC 90 , Յ0.06 g/ml) strains when the CLSI breakpoint criteria were applied (Table 2) .
Gentamicin was the most potent aminoglycoside tested against S. pneumoniae (MIC 50 and MIC 90 , 16 g/ml) ( Tables 1 and 2 ) and H. influenzae (MIC 50 and MIC 90 , 2 g/ml), followed by arbekacin (MIC 50 , 32 g/ml, and MIC 90 , 64 g/ml for S. pneumoniae; MIC 50 and MIC 90 , 4 g/ml for H. influenzae) and amikacin (MIC 50 , 64 g/ml, and MIC 90 , 128 g/ml for S. pneumoniae; MIC 50 , 8 g/ml, and MIC 90 , 16 g/ml for H. influenzae) ( Table 1) .
Antimicrobial activity of arbekacin and comparators tested against antimicrobial-resistant organism subsets. MIC 90 values of aminoglycosides were generally elevated for ESBL-producing E. coli and ESBL-and KPC-producing K. pneumoniae (Tables 3 and  4) . Based on MIC 50 results, arbekacin (MIC 50 , 2 g/ml, and MIC 90 , 16 g/ml) was 2-, 4-, and 16-fold more potent than ami- kacin (MIC 50 , 4 g/ml, and MIC 90 , 32 g/ml), gentamicin (MIC 50 , 8 g/ml, and MIC 90 , Ͼ128 g/ml), and tobramycin (MIC 50 , 32 g/ml, and MIC 90 , 512 g/ml) against ESBL-producing E. coli, respectively (Table 4) , and inhibited 66.7% of gentamicin-resistant strains at a MIC of Յ8 g/ml (Table 3) .
Arbekacin (MIC 50 , 0.5 g/ml, and MIC 90 , 16 g/ml) and amikacin (MIC 50 , 2 g/ml, and MIC 90 , Ͼ512 g/ml; 84.2% susceptible) were the most potent aminoglycosides tested against ESBLproducing K. pneumoniae, and arbekacin (MIC 50 , 8 g/ml, and MIC 90 , 16 g/ml) and gentamicin (MIC 50 , 2 g/ml, and MIC 90 , 128 g/ml; 50.0% susceptible) were the most potent aminoglycosides tested against KPC-producing K. pneumonia (Table 4) . Moreover, arbekacin was active against 61.5% of gentamicin-resistant strains at Յ8 g/ml (Table 3) . All aminoglycosides exhibited good activity against ceftazidime-resistant E. cloacae (MIC 50 , 0.5 to 2 g/ml, and MIC 90 , 1 to 2 g/ml), whereas arbekacin (MIC 50 , 0.5 g/ml, and MIC 90 , 1 g/ml) and amikacin (MIC 50 , 2 g/ml, and MIC 90 , 4 g/ml) were the most potent (i.e., they had the lowest MIC 50 and MIC 90 values) aminoglycosides tested against ceftazidime-resistant C. freundii (Tables 3 and 4 ). All ceftazidime-resistant strains of E. cloacae and C. freundii (MIC 50 , 0.5 g/ml, and MIC 90 , 1 g/ml for both) were susceptible to imipenem (Table 4) .
When tested against imipenem-resistant P. aeruginosa, arbekacin (MIC 50 , 4 g/ml, and MIC 90 , 64 g/ml) inhibited 64.5% of strains at Յ8 g/ml, and it was the most potent aminoglycoside tested against these organisms (Tables 3 and 4) . Moreover, arbekacin inhibited 69.2% of MBL-producing strains and 88.9% of strains nonsusceptible to amikacin, gentamicin, and tobramycin at a MIC of Յ8 g/ml (Table 3) . Tobramycin (MIC 50 , 32 g/ml, and MIC 90 , Ͼ128 g/ml) inhibited only 41.9% of imipenem-resistant P. aeruginosa strains at the CLSI susceptible breakpoint of Յ4 g/ml (Table 4) . Arbekacin was also the most potent aminoglycoside tested against imipenem-resistant A. baumannii (MIC 50 , 8 g/ml, and MIC 90 , 32 g/ml) ( Table 4 ) and inhibited 58.0% of strains at Յ8 g/ml (Table 3) .
Arbekacin was very active against MRSA (highest MIC, 4 g/ ml; one strain), including S. aureus with heterogeneous resistance to vancomycin (hVISA), community-acquired MRSA (CA-MRSA) (MIC 50 , 0.5 g/ml, and MIC 90 , 1 g/ml for both groups) and gentamicin-resistant strains (MIC 50 , 1 g/ml, and MIC 90 , 2 g/ml) ( Table 3 ). Gentamicin and amikacin were active against 68.6 and 90.0% of MRSA strains at the respective CLSI susceptible breakpoints (Table 4) .
DISCUSSION
The initial antimicrobial management of patients with pneumonia is driven mainly by the understanding of causative pathogens (16) . The frequency of occurrence of organisms observed in the current study is very similar to that reported by other investigators. The main reported causes of health care-associated pneumonia are S. aureus, P. aeruginosa, and the Enterobacteriaceae Klebsiella spp., Enterobacter spp., E. coli, and Serratia spp. (11, 17, 18) . In the present study, S. aureus and P. aeruginosa were the most common causes of PHP (non-VAP and VAP), followed by Klebsiella spp. and Enterobacter spp. Although in the current study we could not separate community-acquired pneumonia that requires hospitalization from hospital-acquired pneumonia (HAP), the fact that S. pneumoniae and H. influenzae combined were responsible for only 5.5% of cases indicates that the vast majority of cases included in the study were HAP.
Inhaled antimicrobials have a long history of use in the treat- f Isolates that were nonsusceptible to amikacin (MIC, Ն32 g/ml), gentamicin (MIC, Ն8 g/ml), and tobramycin (MIC, Ն8 g/ml) (14) . a ESBL, extended spectrum ␤-lactamase, CAZ-R, ceftazidime-resistant (MIC, Ն16 g/ml); IMI-R, imipenem-resistant (MIC, Ն8 g/ml); MRSA, methicillin-resistant S. aureus (14) . b Criteria as published by the CLSI (2014) (14) . -, no criteria available. ment of lower respiratory tract infections. These therapies have clearly transformed the management of cystic fibrosis patients, and there has been growing interest in the use of inhaled antimicrobials in other clinical settings, such as in cases of HAP and VAP (19) . Aerosolized tobramycin was the first antimicrobial agent approved by the U.S. FDA for inhaled therapy, and the aminoglycoside agents have been a mainstay of inhaled antimicrobial therapy for many years, mainly due to their spectrum of antimicrobial activity (19) (20) (21) . In the present study, we evaluated the in vitro activity of arbekacin against 904 contemporary (2012) isolates from PHP collected in 62 U.S. medical centers. The collection included at least 100 isolates from nine of the 10 most frequently isolated bacterial species from HAP (only S. maltophilia was not tested), and arbekacin demonstrated potent activity and good coverage against these organisms, with 87.3 and 91.8% of all strains being inhibited at Յ16 and Յ32 g/ml, respectively. Arbekacin was the most potent aminoglycoside tested against S. aureus and P. aeruginosa, and these two organisms together comprised more than one-half of the organisms isolated from PHP in U.S. medical centers. Furthermore, arbekacin potency was similar or superior to the most potent comparators in its antimicrobial class (namely, amikacin, gentamicin, and tobramycin) when tested against Acinetobacter spp. and the Enterobacteriaceae species commonly isolated from PHP. MDR Gram-negative organisms, especially ESBL-and KPCproducing Enterobacteriaceae and carbapenem-resistant P. aeruginosa and Acinetobacter spp., represent important therapeutic challenges, especially when causing serious infections such as pneumonia (11, 16, 17) . The results of this investigation also showed that arbekacin retained activity against many of these MDR organisms. Arbekacin was the most potent aminoglycoside tested against ESBL-producing E. coli and inhibited 66.7% of gentamicin-resistant strains at a MIC of Յ8 g/ml. When tested against K. pneumoniae-producing ESBL and/or KPC, arbekacin was slightly more active (2-to 16-fold lower MIC 50 ) than amikacin or tobramycin, and although arbekacin was slightly (2-fold) less active than gentamicin when tested against KPC-producing K. pneumoniae, it inhibited 59.5% of gentamicin-resistant strains at a MIC of Յ8 g/ml.
The multiple resistance mechanisms present in P. aeruginosa and A. baumannii isolates make these organisms major clinical concerns. The combination of various mechanisms or even the expression of a single broad-spectrum resistance mechanism turns these bacteria resistant to multiple commercially available antimicrobials and, consequently, makes the therapy of these infections extremely difficult (22, 23) . Furthermore, it has been suggested that patients with VAP attributed to P. aeruginosa and Acinetobacter spp. may benefit from adjunctive aerosolized therapy (24) . In the present study, arbekacin demonstrated greater activity against P. aeruginosa and Acinetobacter spp., including MDR strains, than other agents in its class and retained activity against a considerable proportion of strains that are resistant to aminoglycosides commonly used in clinical practice when applying clinical susceptible breakpoints (4, 14, 15) .
In summary, arbekacin was notably active against a large collection of contemporary (2012) organisms isolated from hospitalized patients with pneumonia in U.S. medical centers, as well as against a collection of well-characterized MDR organisms selected from species commonly isolated from patients with pneumonia. The results of this study indicate that arbekacin could represent a valuable addition to the limited group of antimicrobials currently available for the inhalation treatment of PHP caused by MDR organisms.
